HOUSTON, March 18, 2019 /PRNewswire/ -- Soliton,
Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), has been invited
to present at Oppenheimer's 29th Annual Healthcare
Conference on Wednesday, March 20,
2019 at The Westin New York Grand Central in New York
City. The conference is one of the most important investor
conferences in the medical device industry, as well as other
healthcare related industries.
![Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company’s first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to accelerate the removal of unwanted tattoos (RAP device). Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company’s first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to accelerate the removal of unwanted tattoos (RAP device).](https://mma.prnewswire.com/media/836799/Soliton_Logo.jpg)
"We are proud to have been invited to present to investors at
this prestigious conference," said Dr. Chris Capelli, Soliton's President and
CEO. "To be included amongst the thought leaders and
innovators in this sector is indeed an honor. We believe the
discussion of our Rapid Acoustic Pulse (RAP) technology used to
target tattoo removal and our newer related technology that has the
potential to treat cellulite, our compelling clinical data, and our
recent IPO will be a highlight of the conference."
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first planned commercial product is designed to use rapid
pulses of designed acoustic shockwaves in conjunction with existing
lasers to accelerate the removal of unwanted tattoos (RAP device).
In addition, higher energy versions of acoustic pulse devices are
in early stages of development for potential stand-alone treatment
of cellulite and other indications. Both products
are investigational and are not available for sale in the United States.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of Soliton RAP to
receive FDA clearance. These statements relate to future
events, future expectations, plans and prospects. Although Soliton
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. Soliton has
attempted to identify forward-looking statements by terminology
including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under in our SEC filings, including under the heading "Risk
Factors" in the Form 1-A we filed with the SEC on February 13, 2019. Any forward-looking
statements contained in this release speak only as of its date.
Soliton undertakes no obligation to update any forward-looking
statements contained in this release to reflect events or
circumstances occurring after its date or to reflect the occurrence
of unanticipated events.
CONTACT:
Joe Dorame, Joe Diaz & Robert
Blum
Lytham Partners, LLC
602-889-9700
soly@lythampartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-to-present-at-oppenheimer-29th-annual-healthcare-conference-on-march-20-2019-300813664.html
SOURCE Soliton, Inc.